|
Variable
|
Single common mutation (n = 115)
|
Compound mutations (n = 106)
|
P
†
|
Double common mutations (n = 5)
|
P
†
|
Common + rare mutations (n = 11)
|
P
†
|
Rare + rare mutations (n = 13)
|
P
†
|
Rare + T790M mutations (n = 8)
|
P
†
|
Common + T790M mutations (n = 69)
|
P
†
|
|---|
|
Sex
|
|
Female
|
56
|
55
|
0.635
|
1
|
0.368
|
6
|
0.711
|
6
|
0.862
|
4
|
0.943
|
38
|
0.402
|
|
Male
|
59
|
51
|
4
|
5
|
7
|
4
|
31
|
|
Age (years)
|
|
< 60
|
57
|
63
|
0.141
|
2
|
0.675
|
5
|
0.794
|
8
|
0.413
|
7
|
0.063
|
41
|
0.195
|
|
≥ 60
|
58
|
43
|
3
|
6
|
5
|
1
|
28
|
|
Smoking status
|
0.270
| |
0.118
| |
0.795
| |
0.442
| |
0.795
| |
0.022
|
|
Non-smoker
|
69
|
69
|
1
|
5
|
4
|
5
|
54
|
|
Smoker
|
34
|
24
|
3
|
3
|
4
|
3
|
11
|
|
Unknown
|
12
|
13
|
1
|
0
|
5
|
0
|
4
|
|
Tumour status
|
0.034
| |
0.592
| |
0.782
| |
0.753
| |
0.103
| |
0.064
|
|
Recurrence
|
36
|
20
|
1
|
3
|
3
|
0
|
13
|
|
Initial IIIb–IV
|
79
|
86
|
4
|
8
|
10
|
8
|
56
|
|
ECOG PS
|
|
0–1
|
107
|
96
|
0.501
|
4
|
0.327
|
9
|
0.212
|
13
|
0.326
|
6
|
0.071
|
64
|
0.941
|
|
2–4
|
8
|
10
|
1
|
2
|
0
|
2
|
5
|
|
Pathology
|
0.529
| |
0.141
| |
0.672
| |
0.899
| |
0.948
| |
0.534
|
|
ADC
|
110
|
102
|
4
|
10
|
13
|
8
|
67
|
|
SCC
|
5
|
2
|
0
|
1
|
0
|
0
|
1
|
|
LELC
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
|
ASC
|
0
|
1
|
0
|
0
|
0
|
0
|
1
|
|
Timing of TKI
|
0.720
| |
0.914
| |
0.835
| |
0.803
| |
0.805
| |
0.460
|
|
First line
|
52
|
55
|
2
|
5
|
6
|
3
|
39
|
|
Second line
|
55
|
46
|
3
|
6
|
7
|
5
|
25
|
|
Third line
|
7
|
4
|
0
|
0
|
0
|
0
|
4
|
|
Fourth line
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
|
TKI selection
|
0.034
| |
0.981
| |
0.592
| |
0.214
| |
0.161
| |
0.021
|
|
Gefitinib
|
64
|
47
|
3
|
5
|
4
|
2
|
33
|
|
Erlotinib
|
26
|
41
|
1
|
4
|
4
|
4
|
28
|
|
Icotinib
|
25
|
18
|
1
|
2
|
5
|
2
|
8
|
|
Response to TKIs
|
|
PD
|
10
|
14
|
0.088
|
1
|
0.148
|
2
|
0.652
|
2
|
0.328
|
4
|
0.012
|
5
|
0.293
|
|
SD
|
21
|
33
|
1
|
3
|
5
|
1
|
22
|
|
PR
|
77
|
54
|
3
|
5
|
5
|
3
|
39
|
|
CR
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
NE
|
6
|
5
|
0
|
1
|
1
|
0
|
3
|
- ECOG PS Eastern Cooperative Oncology Group performance status, ADC adenocarcinoma, SCC squamous cell carcinoma, LELC lymphoepithelioma-like carcinoma, ASC adenosquamous carcinoma, PD progressive disease, SD stable disease, PR partial response, CR complete response, NE not evaluated, TKI tyrosine kinase inhibitor, PFS progression-free survival, OS overall survival
- †All variables of different subgroups were compared with the single common mutation group; P < 0.05 was defined as significantly different
